Merck halts leukemia trials after adverse event

Vertex says that Merck suspended two clinical trials of the leukemia drug MK-0457 after one of the patients in the study developed a heart condition--QTc prolongation--caused by a disruption in the organ's electrical system. Researchers called for a full review of the data available on the drug, which is in Phase II as the lead Aurora kinase inhibitor included in a development pact between the two companies. The drug is also in an early-stage combination trial with dasatinib. Another Aurora kinase inhibitor included in the collaboration, MK-6592, has been dumped after it failed to deliver on its pharmacokinetic goals in Phase I.

- see this release
- check out the AFX report for more

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.